IMVT
Immunovant, Inc.Company Information
- Company Name
- Immunovant, Inc.
- CIK
- CIK0001764013
- Category
- Large accelerated filer
- Ticker: Exchange
- IMVT: Nasdaq
- Fiscal Year End
- March 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- IMVT
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-12
- Last sale
- 2026-09-23
- Shares purchased (TTM)
- 16,666,666
- Shares sold (TTM)
- 497,835
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 106,190,444
- Shares outstanding
- 205,545,373
- Ownership
- 51.66%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 3.67%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred Stock | - | - | - | - | - | - | - | - | - | 0 | -0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 798 | 902 | 995 | 522 | 599 | 714 | 375 | 473 | 560 | 635 | 691 | 270 | ||||||
| Accounts Receivable Net Current | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 5 | 1 | 1 | ||||||
| Prepaid Expense Current | 53 | 43 | 47 | 50 | 51 | 51 | 36 | 33 | 27 | 25 | 19 | 20 | ||||||
| Income Taxes Receivable | - | 3 | - | - | - | 0 | - | - | - | 0 | - | - | ||||||
| Assets Current | 851 | 949 | 1,043 | 574 | 652 | 768 | 413 | 507 | 589 | 666 | 711 | 291 | ||||||
| Operating Lease Right Of Use Asset | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 1 | 8 | 9 | 9 | 9 | 8 | 8 | 8 | - | 0 | - | - | ||||||
| Assets | 852 | 957 | 1,052 | 583 | 661 | 776 | 421 | 516 | 590 | 666 | 711 | 292 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 10 | 8 | 9 | 7 | 8 | 18 | 20 | 21 | 11 | 7 | 4 | 8 | ||||||
| Accrued Liabilities Current | - | 97 | - | - | - | 51 | 48 | 46 | 34 | 41 | 28 | 32 | ||||||
| Operating Lease Liability Current | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Other Liabilities Current | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Liabilities Current | 117 | 104 | 66 | 63 | 53 | 69 | 68 | 67 | 45 | 49 | 32 | 40 | ||||||
| Liabilities | 117 | 104 | 66 | 63 | 53 | 69 | 68 | 67 | 45 | 49 | 32 | 40 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 2,633 | 2,597 | 2,582 | 2,005 | 1,967 | 1,945 | 1,483 | 1,469 | 1,456 | 1,442 | 1,430 | 950 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | -1 | 1 | ||||||
| Retained Earnings Accumulated Deficit | -1,898 | -1,745 | -1,597 | -1,487 | -1,360 | -1,240 | -1,133 | -1,022 | -913 | -826 | -750 | -699 | ||||||
| Stockholders Equity | 735 | 853 | 986 | 520 | 609 | 707 | 353 | 449 | 545 | 618 | 679 | 252 | ||||||
| Liabilities And Stockholders Equity | 852 | 957 | 1,052 | 583 | 661 | 776 | 421 | 516 | 590 | 666 | 711 | 292 | ||||||
| Series A Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Excluding Series A Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | - | - | - | - | - | - | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 206 | 204 | 203 | 175 | 171 | 170 | 147 | 147 | 146 | 146 | 145 | 131 | ||||||
| Shares Outstanding | 206 | 204 | 203 | 175 | 171 | 170 | 147 | 147 | 146 | 146 | 145 | 131 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialImmunovant, Inc. (IMVT) — SEC Financial Statements & Analysis
Immunovant, Inc. (IMVT) is a biological products, (no diagnostic substances) company, incorporated in DE. Immunovant, Inc. trades on Nasdaq as: IMVT. Immunovant, Inc. (IMVT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Immunovant, Inc. carries a market cap of $7.92B, a P/E ratio of -14.71x, a P/B ratio of 10.77x, an enterprise value of $7.12B, and an EV/EBITDA multiple of -13.90x. On profitability, it posts a Return on Equity (ROE) of -80.10% and a Return on Assets (ROA) of -71.10%. Per share, it reports EPS of $-2.62, diluted EPS of $-2.62, free cash flow per share of $-2.02, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 20.32% year-over-year and EPS growth of 0.03% year-over-year. On the balance sheet, it maintains a current ratio of 7.27x, a quick ratio of 6.82x, working capital of $734.08M, a debt-to-equity ratio of 0.16x, a debt ratio of 0.14, an interest coverage ratio of -19.66x, free cash flow of $-414.31M (TTM), and net debt of $-797.80M. Figures sourced from SEC EDGAR.
- Market Cap
- $7.92B
- P/E TTM
- -14.71x
- EPS TTM
- $-2.62
- P/B TTM
- 10.77x
- ROE TTM
- -80.10%
- ROA TTM
- -71.10%
- Debt To Equity
- 0.16x
- Free Cash Flow TTM
- $-414.31M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Immunovant, Inc. in?
Immunovant, Inc. (IMVT) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does IMVT trade on?
Immunovant, Inc. (IMVT) trades on the Nasdaq.
Where is Immunovant, Inc. incorporated?
Immunovant, Inc. is incorporated in DE.
When was Immunovant, Inc. (IMVT)'s most recent SEC filing?
Immunovant, Inc. (IMVT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is IMVT's market cap?
Immunovant, Inc. (IMVT) has a market capitalization of $7.92B as of 2026-06-30.
What is IMVT's EPS (earnings per share)?
Immunovant, Inc. (IMVT)'s trailing twelve month EPS is $-2.62 as of 2026-06-30.
What is IMVT's ROE (return on equity)?
Immunovant, Inc. (IMVT)'s trailing twelve month Return on Equity (ROE) is -80.10% as of 2026-06-30.
What is IMVT's ROA (return on assets)?
Immunovant, Inc. (IMVT)'s trailing twelve month Return on Assets (ROA) is -71.10% as of 2026-06-30.
What is IMVT's EV/EBITDA?
Immunovant, Inc. (IMVT)'s trailing twelve month EV/EBITDA is -13.90x as of 2026-06-30.